Verona Pharma PLC (VRNA, Financial) is set to release its Q3 2024 earnings on Nov 4, 2024. The consensus estimate for Q3 2024 revenue is $2.02 million, and the earnings are expected to come in at -$0.64 per share. The full year 2024's revenue is expected to be $7.79 million and the earnings are expected to be -$2.41 per share. More detailed estimate data can be found on the Forecast page
Verona Pharma PLC (VRNA, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Verona Pharma PLC (VRNA) for the full year 2024 have increased from $6.03 million to $7.79 million, and for 2025, estimates have risen from $83.94 million to $101.83 million. During the same period, earnings estimates have declined from -$1.64 per share to -$2.41 per share for the full year 2024, and from -$0.79 per share to -$0.80 per share for 2025.
Verona Pharma PLC (VRNA, Financial) Reported History
In the previous quarter of December 31, 2022, Verona Pharma PLC's (VRNA) actual revenue was $0.46 million, which missed analysts' revenue expectations of $3.57 million by -87.17%. Verona Pharma PLC's (VRNA) actual earnings were -$0.88 per share, which missed analysts' earnings expectations of -$0.377 per share by -133.42%. After releasing the results, Verona Pharma PLC (VRNA) was down by -10.51% in one day.
Verona Pharma PLC (VRNA, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 8 analysts, the average target price for Verona Pharma PLC (VRNA) is $38.31 with a high estimate of $50 and a low estimate of $31.50. The average target implies an upside of 12.92% from the current price of $33.93.
Based on GuruFocus estimates, the estimated GF Value for Verona Pharma PLC (VRNA, Financial) in one year is $0, suggesting a downside of -100% from the current price of $33.93.
Based on the consensus recommendation from 8 brokerage firms, Verona Pharma PLC's (VRNA, Financial) average brokerage recommendation is currently 1.6, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
